DiaMedica Therapeutics Inc. (DMAC) has a negative trailing P/E of -8.8, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -11.32%.
Criteria proven by this page:
Overall SharesGrow Score: 51/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -4.7 | -0.27 | 8.36 | 0.00 | - |
| 2017 | -6.8 | -0.13 | 36.25 | 0.00 | - |
| 2018 | -3.9 | -1.41 | 1.32 | 45.07 | - |
| 2019 | -5.5 | -0.27 | 7.63 | 0.00 | - |
| 2020 | -12.9 | 1.05 | 6.11 | 0.00 | - |
| 2021 | -5.7 | 0.34 | 1.76 | 0.00 | - |
| 2022 | -3.1 | 0.15 | 1.31 | 0.00 | - |
| 2023 | -4.8 | -0.31 | 1.81 | 0.00 | - |
| 2024 | -9.0 | 0.00 | 5.39 | 0.00 | - |
| 2025 | -11.4 | -0.68 | 6.66 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-0.47 | $0.00 | $-2.22M | - |
| 2017 | $-0.72 | $0.00 | $-4.26M | - |
| 2018 | $-0.74 | $500K | $-5.73M | -1146.8% |
| 2019 | $-0.89 | $0.00 | $-10.65M | - |
| 2020 | $-0.78 | $0.00 | $-12.29M | - |
| 2021 | $-0.65 | $0.00 | $-13.59M | - |
| 2022 | $-0.52 | $0.00 | $-13.68M | - |
| 2023 | $-0.60 | $0.00 | $-19.38M | - |
| 2024 | $-0.60 | $0.00 | $-24.44M | - |
| 2025 | $-0.70 | $0.00 | $-32.77M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.76 | $-0.92 – $-0.60 | $54M | $54M – $54M | 3 |
| 2027 | $-0.88 | $-0.88 – $-0.88 | $2.79M | $2.79M – $2.79M | 3 |
| 2028 | $-0.89 | $-1.19 – $-0.33 | $14.05M | $14.01M – $14.08M | 3 |
| 2029 | $-0.67 | $-0.67 – $-0.67 | $39.6M | $39.6M – $39.6M | 1 |
| 2030 | $-0.33 | $-0.33 – $-0.33 | $117.78M | $117.78M – $117.78M | 1 |
